AFAP1L2

Across TCGA pan-cancer cohorts, AFAP1L2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated AFAP1L2 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher AFAP1L2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AFAP1L2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, UCEC, and LSCC are the cancer types where AFAP1L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.897	0.315	<.001	40	view →
UCEC	OS	Median	III,IV	0.492	0.884	.031	4	view →
LSCC	OS	Tertile	All	0.728	0.915	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

AFAP1L2–CCRCC (DFS)

Open the CCRCC breakdown →